Telehealth providers in Louisiana
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
Telehealth prescribing is allowed in Louisiana, but not asynchronous care. What Louisiana requires of telehealth prescribers and pharmacies, plus listings with their verification status.
Louisiana at a glance
- Pharmacy regulator
- Louisiana Board of Pharmacy
- 503A framework
- Follows the federal 503A framework
- Telehealth prescribing
- Regulatory: Telehealth allowed
- Asynchronous prescribing
- Regulatory: Async not allowed
- Compounded GLP-1 access
- Regulatory: Compounded GLP-1 limited
Telehealth providers serving Louisiana
Prescription peptides through an online assessment and a licensed provider review, shipped from a licensed U.S. compounding pharmacy.
Telehealth provider · 17 products · partner lists from $172 a month · Says it serves Louisiana (not yet confirmed)
- Prescription only, no research-use-only sales
- Public cancellation and refund policy
We may earn a commission from these links.
Telehealth prescribing rules in Louisiana
Act 322 of 2023 (effective January 1, 2024) moved Louisiana's physician telemedicine provisions out of the Medical Practice Act and into the Louisiana Telehealth Access Act. La. R.S. 37:1271 now only requires a license to practice medicine, except as provided in that Act, and the separate telemedicine license statute (R.S. 37:1276.1) was repealed. R.S. 40:1223.3 defines telehealth as healthcare services delivered through electronic communications, information technology, asynchronous store-and-forward transfer technology, or synchronous interaction, and excludes fax and any e-mail or text message that is not HIPAA compliant. R.S. 40:1223.4 requires licensing boards to adopt telehealth rules that apply the in-person standard of care, do not require an in-person history or exam before a telehealth encounter, and require an in-person history or exam before prescribing a controlled dangerous substance unless a rule or R.S. 37:1271.1 allows it. The Board of Medical Examiners has not updated its telemedicine rules (Louisiana Administrative Code 46:XLV.7501 and following, last amended in 2019): section 7503 still defines telemedicine as simultaneous two-way video and audio (audio-only in limited cases), section 7505 says an online, electronic or written mail message does not satisfy the standard of care, and section 7513 bars telemedicine for obesity treatment. Act 345 of 2026 (R.S. 40:1223.4(D), effective May 22, 2026) stops the Board from prohibiting telehealth for obesity or weight management when the provider conducts a synchronous interaction. The Act does not itself require a live visit, but it leaves the Board's obesity rule enforceable against asynchronous obesity care. The Board has proposed a 2026 rule on obesity medication (LAC 46:XLV.6901 and following) that is not yet adopted. This record classifies asynchronous prescribing as not allowed because the Board of Medical Examiners rule in force defines telemedicine as simultaneous two-way video and audio and says an online, electronic or written mail message does not meet the standard of care. That rule speaks of a message rather than a questionnaire by name, and this record treats a questionnaire alone as not enough on that basis. The 2021 and 2023 statutes count asynchronous store-and-forward transfer as telehealth but do not say a relationship may be formed or a drug prescribed that way, and the Board has not revised its rule. [2] [3] [4] [5] [6] [7] [13] [14]
Compounded GLP-1 access in Louisiana
In spring 2023, while semaglutide was still in shortage, the Louisiana Board of Pharmacy told in-state compounders to stop compounding semaglutide made from unapproved salt forms (such as semaglutide sodium or acetate) and told out-of-state compounders not to ship such products into Louisiana; the Board's director clarified that compounding with the approved base form was not banned at the time. Since the FDA shortage allowances ended in 2025, compounded semaglutide and tirzepatide are limited to documented patient-specific needs in Louisiana as elsewhere. Act 345 of 2026 protects telehealth for obesity and weight management only when the provider conducts a live, synchronous interaction, and the Board of Medical Examiners rule against telemedicine for obesity treatment remains enforceable against care with no live interaction. [1] [13] [14] [15] [17]
Research use only sellers in Louisiana
Only Louisiana-permitted pharmacies, including nonresident pharmacies permitted under La. R.S. 37:1232, may dispense prescription drugs to Louisiana patients. The Louisiana Board of Pharmacy has described semaglutide salt forms sold as "research use only" as not intended for human use, and "research use only" peptides sold for injection are unapproved new drugs under federal law. [8] [15] [18]
How to check a telehealth provider in Louisiana
- Confirm the prescriber is licensed or registered to treat patients located in Louisiana; the telehealth rules above explain what Louisiana requires. [2] [3] [4] [5] [6] [7] [13] [14]
- Ask which pharmacy will fill the prescription and check it in the Louisiana Board of Pharmacy license lookup. [1] [8] [9] [10] [11] [12] [15] [16] [19]
- Get the full price in writing first: consult fees, membership fees, and the medication itself.
- Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Louisiana. [8] [15] [18]
Common questions in Louisiana
Does Louisiana let out-of-state doctors prescribe by telemedicine?
Only with Louisiana authorization. La. R.S. 37:1271 requires a Louisiana license to practice medicine, except as the Louisiana Telehealth Access Act provides. The separate telemedicine license statute (R.S. 37:1276.1) was repealed effective January 1, 2024, and R.S. 40:1223.4 now calls for board rules on licensing or registration of out-of-state telehealth providers. Check the Louisiana State Board of Medical Examiners lookup. [2] [3] [4] [6]
What does an out-of-state pharmacy need to ship compounded peptides to Louisiana?
A Louisiana Board of Pharmacy permit under La. R.S. 37:1232. The pharmacy must give the Board its latest inspection reports from its home state, FDA, and DEA, and keep Louisiana prescription records readily retrievable. Verify the permit on the Board's lookup before ordering. [1] [8]
Sources
- [1]Louisiana Board of Pharmacy
- [2]Louisiana State Board of Medical Examiners
- [3]La. R.S. 37:1271, License to practice medicine required (Louisiana State Legislature, text effective January 1, 2024)
- [4]Louisiana Act 322 of 2023 (Senate Bill 66), telehealth: amends R.S. 37:1262(4), 37:1271 and 40:1223.3 to 1223.5, repeals R.S. 37:1276.1
- [5]La. R.S. 40:1223.3, Louisiana Telehealth Access Act definitions (Louisiana State Legislature)
- [6]La. R.S. 40:1223.4, Telehealth; rulemaking required (Louisiana State Legislature)
- [7]Louisiana Administrative Code Title 46, Part XLV, section 7503, Telemedicine definitions (LSBME rules)
- [8]La. R.S. 37:1232, Nonresident pharmacy
- [9]Louisiana Board of Pharmacy: Title 37, chapter 14, Pharmacy Practice Act
- [10]Louisiana Administrative Code Title 46, Part LIII, Pharmacists (Board of Pharmacy rules)